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Abstract
Background: Loss of vision in glaucoma is due to apoptotic retinal ganglion cell loss. While p53 modulates apoptosis, gene
association studies between p53 variants and glaucoma have been inconsistent. In this study we evaluate the association
between a p53 variant functionally known to influence apoptosis (codon 72 Pro/Arg) and the subset of primary open angle
glaucoma (POAG) patients with early loss of central visual field.
Methods: Genotypes for the p53 codon 72 polymorphism (Pro/Arg) were obtained for 264 POAG patients and 400 controls
from the U.S. and in replication studies for 308 POAG patients and 178 controls from Australia (GIST). The glaucoma patients
were divided into two groups according to location of initial visual field defect (either paracentral or peripheral). All cases
and controls were Caucasian with European ancestry.
Results: The p53-PRO/PRO genotype was more frequent in the U.S. POAG patients with early visual field defects in the
paracentral regions compared with those in the peripheral regions or control group (p = 2.761025). We replicated this
finding in the GIST cohort (p = 7.361023, and in the pooled sample (p = 6.661027) and in a meta-analysis of both the US
and GIST datasets (1.361026, OR 2.17 (1.58–2.98 for the PRO allele).
Conclusions: These results suggest that the p53 codon 72 PRO/PRO genotype is potentially associated with early
paracentral visual field defects in primary open-angle glaucoma patients.
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Introduction
Adult-onset primary open-angle glaucoma (POAG) is charac-
terized by an irreversible degeneration of the optic nerve that is a
common cause of blindness worldwide. POAG is phenotypically
and genetically complex and it is likely that multiple genetic and
environmental factors play a role in its etiology. Elevated
intraocular pressure (IOP) is a major risk factor for optic nerve
disease in glaucoma; however, most ocular hypertensive patients
do not develop optic nerve degeneration [1] and a number of
studies show that POAG patients can develop optic nerve disease
despite IOPs in the normal range [2]. Randomized clinical trials,
including the Collaborative Normal-tension Glaucoma Study
report that lowering IOP does not always result in prevention of
progressive visual loss [3]. Collectively these results suggest that
some glaucoma patients have a greater susceptibility to optic nerve
disease than others. The inherent optic nerve susceptibility
exhibited by glaucoma patients may be influenced by a specific
set of genetic and/or environmental risk factors, which could be
new therapeutic targets for this disease.
Visual field defects in glaucoma patients frequently develop in
the periphery and gradually extend to the central region. In a
subset of patients the initial functional defect appears in the central
visual field as a paracentral scotoma, representing a loss of the
maculopapillary nerve fiber layer bundles. Glaucoma patients
presenting with early-stage paracentral scotomas are more likely to
have systemic risk factors for glaucoma (hypotension, migraine,
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Raynaud’s phenomenon, and sleep apnea) [4] are more likely to
become blind from glaucoma [5] and have lower intraocular
pressures than patients with initial defects in the periphery [4,6].
Together, these observations suggest that formation of paracentral
scotomas at early stages of the disease characterizes a subtype of
glaucoma, or glaucoma endophenotype, likely to be dependent on
a specific set of genetic and environmental risk factors.
Loss of retinal ganglion cells in glaucoma is dependent on the
balance of cellular pro-survival and pro-death pathways. Proteins
that participate in these pathways are excellent candidates for
factors that could influence the susceptibility of retinal ganglion
cells to glaucoma-related apoptosis. One of the most important
apoptotic regulatory proteins is the tumor suppressor protein p53,
which responds to diverse cellular stresses to regulate cell cycle
arrest, apoptosis, senescence, and DNA repair [7]. TP53 (coding
for p53) is expressed in retinal ganglion cells under conditions that
would stimulate apoptosis [8–10] and in an experimental model of
glaucoma [11]. Family-based linkage studies have provided
evidence for a glaucoma locus on chromosome 17 p that includes
TP53 [12,13].
TP53 has a common DNA sequence polymorphism that results
in either proline (p53-PRO) or arginine (p53-ARG) at amino-acid
position 72 (dbSNP: rs1042522) in the p53 protein. This
polymorphism occurs in the p53 proline-rich PXXP domain,
which is necessary for the protein to fully induce apoptosis [14].
The proline and arginine variants significantly affect the biological
activity of p53, although these effects are highly dependent on the
conditions of the study. p53-PRO has increased apoptotic activity
in cancer cells in hypoxic conditions [15] and is associated with
age-dependent senescence in cultured fibroblasts [16]. p53-ARG
increases transcriptional activity of apoptotic related genes in
human osteosarcoma cell lines and has higher apoptotic activity in
most tumor cells [17]. The apoptotic activity of the codon 72
variants in retinal ganglion cells or other cell types involved in
glaucoma is not known.
The p53 codon 72 polymorphism has been studied previously as
a risk factor for glaucoma and a consistent association has not been
found [18–28]. The lack of consistent findings among these studies
could be due to variable sample size, ascertainment methodolo-
gies, glaucoma case definitions, genotyping methods, and variation
in genotypic and allelic frequencies related to population
substructure. The p53-PRO allele is the ancestral allele in the
African population, while the p53-ARG allele is much more
common in European populations [29].
In this study we examine the association between POAG and
the p53 codon 72 polymorphism in a Caucasian cohort of
European ancestry from the United States and replicate our
findings in an independent Caucasian cohort of European ancestry
from Australia. The results of our study suggest that the p53-
PRO/PRO genotype is potentially associated with a specific
glaucoma endophenotype that includes paracentral scotoma
formation at an early stage in the disease.
Materials and Methods
Participants
The tenets of Helsinki were adhered to and ethics approval was
obtained from the Massachusetts Eye and Ear Infirmary (MEEI)
institutional review board, and the ethics committees of the Royal
Hobart Hospital and the Royal Victorian Eye and Ear Hospital.
Written informed consent was obtained from all study participants
at both the Massachusetts Eye and Ear Infirmary and the Royal
Victorian Eye and Ear Hospital.
264 patients affected with adult onset primary open angle
glaucoma (POAG) [64 patients affected with normal tension
glaucoma (NTG) and 200 with HT-POAG (‘high-tension’-
POAG)], and 400 unaffected individuals were recruited from the
Glaucoma Consultation Service and the Comprehensive Oph-
thalmology Service at the Massachusetts Eye and Ear Infirmary.
An additional 308 unrelated people with POAG and 178 controls
were recruited through the Glaucoma Inheritance Study in
Tasmania (GIST). GIST is derived from a Caucasian population
of European ancestry in southeastern Australia, and specific
features of this glaucoma cohort have been described previously
[23]. All participants had a complete ophthalmological examina-
tion, including funduscopic evaluation of the retina and slit-lamp
evaluation of the lens. Any patient with retinal or lenticular
pathology that could confound the visual field analysis was not
included in this study. All of the study participants (all cases and all
controls) from both the U.S. and GIST cohorts are Caucasian with
reported European ancestry. The features of the cases and controls
for both cohorts are presented in Table 1.
Only subjects older than 35 years of age were included in this
analysis. HT-POAG was defined as an IOP greater than or equal
to 22 mm Hg in both eyes, glaucomatous optic nerve damage in
both eyes, and visual field loss in at least one eye. Normal tension
glaucoma (NTG) patients had evidence of optic nerve disease and
visual field defects with IOP less than 22 mm Hg. Intraocular
pressure was measured with a Goldmann tonometer in the clinical
setting during typical clinic hours (9 AM to 5 PM). The recorded
IOP for each patient was the highest known IOP prior to
Table 1. Demographic features of the cases and controls.
CohortGroup N
Female
(%)
Age at diagnosis*
(year)
Maximum IOP
(mm Hg)
Range Mean±SD Range Mean±SD
MEEI All
glaucoma
264 51.5 32–86 61.3611.3{ 9–50 24.865.9{
HT-POAG 200 47.5 32–86 61.4611.3{ 9–50 26.365.5{
NTG 64 64.1{ 34–83 61.0611.6{ 13–21 17.962.2
PS 67 59.7 32–83 60.0611.2{ 9–42 23.865.5{
NS 147 52.4 34–86 62.0611.4{ 12–38 24.665.6{
Controls 400 55.3 39–92 66.0611.3 9–22 16.1+2.6
GIST All
glaucoma
308 60.7{ 24–89 63.1612.4 10–74 25.0+9.4
PS 26 76.9 41–80 63.0610.5 18–36 24.0+5.2
NS 152 60.5 24–89 64.2612.8 10–68 24.2+8.8
Controls 178 70.2 17–95 65.7622.3 NA NA
Pooled All
glaucoma
572 56.5 24–89 62.2611.9{
PS 93 64.5 32–83 60.8611.1{
NS 299 56.5 24–89 63.1612.1{
Controls 578 59.9 17–95 65.9615.5
*For controls, this refers to age at enrollment.
{p =0.02 compared to POAG.
{p,0.05 compared to controls.
Abbreviations: MEEI, Massachusetts Eye and Ear Infirmary; GIST, Glaucoma
Inheritance Study in Tasmania; IOP, Intraocular pressure; HT-POAG, High-
tension POAG; POAG, Primary Open Angle Glaucoma; NTG, Normal Tension
Glaucoma; PS, Paracentral scotoma; NS, Nasal step/arcuate scotoma; NA, Not
available; SD, standard deviation.
doi:10.1371/journal.pone.0045613.t001
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treatment. Controls had IOP less than 22 mmHg, normal optic
nerves and no family history of glaucoma.
Visual Field Scoring
The earliest reliable visual fields demonstrating reproducible
defects on at least two independent tests were selected for each
affected individual. For this analysis we only used Humphrey
automated visual fields (Humphrey Instruments, San Leandro,
California, USA) using either the Standard full threshold or Fast-
Pac programs. To be included in the study the false positive and
negative error rates were less than 20% and the fixation losses
were less than 33%. Visual fields demonstrating advanced disease,
or generalized depression (mean defect .12 dB) were not used for
this analysis. The average pattern deviation in each of 6 regions of
the visual field corresponding to the superior paracentral, inferior
paracentral, superior nasal arcuate, inferior nasal arcuate, superior
nasal step, and inferior nasal step were calculated for each
individual (Figure 1). Patients were classified as having an early-
stage paracentral scotoma (PS) if they had a focal mean pattern
deviation score (PSD) in one of the paracentral regions (either
superior or inferior) greater than 5 dB and also if the focal mean
pattern deviation score, in at least one of the paracentral regions,
was more than 5 dB greater than any other visual field region.
Patients were classified as having nasal step/arcuate scotomas (NS)
if one of the four possible nasal step or arcuate regions had a mean
PSD greater than 5 dB and if one of the four possible regions was
5 dB greater than either of the paracentral regions. Individual eyes
were scored independently, and one eye from each patient was
used for the analysis. If both eyes qualified for the study, the eye
demonstrating the earliest reproducible defect was chosen. 214
visual fields for the MEEI cohort and 178 visual fields for the
GIST cohort met these criteria and were used for this analysis.
Genotyping
DNA was extracted from either peripheral blood samples or
mouthwash samples according to previously published protocols
[30]. A region of exon 4 of the p53 gene containing the p53 codon
72 polymorphism was amplified and sequenced in all patients
using an ABI310 automated sequencer and BIGDYE sequencing
chemistry.
Statistical Analysis
Association analysis was performed using PLINK [31]. Hardy-
Weinberg equilibrium was assessed using the chi-squared test.
Genotype and allele frequencies of the TP53 codon 72 variant
between patients with glaucoma and control subjects were
compared using the Fisher’s exact test. Age-adjusted OR and
95%CI were calculated using logistic regression after adjusting for
age at diagnosis for patients with glaucoma and age at enrollment
for control subjects. The heterogeneity of ORs between cohorts
was evaluated using the Breslow-Day test. Meta-analysis was
performed across cohorts assuming a fixed-effect. Multiple
comparisons were corrected using the Bonferroni method.
Results
Because previous studies suggested that p53 could contribute to
the development of normal-tension glaucoma [4,32], we first
evaluated the association of the p53 codon 72 polymorphism in
the MEEI glaucoma cases with normal tension glaucoma (NTG)
defined as IOP less than 22 at time of diagnosis, as well as in the
MEEI POAG patients with IOPs at diagnosis equal to or greater
than 22 (HT-POAG). The p53-PRO/PRO (proline/proline)
genotype and proline allele was associated with NTG overall
(p = 0.008 and 0.016 respectively), and nominally with POAG
overall (NTG and HT-POAG combined) (p = 0.032 and 0.057
respectively) but not with HT-POAG (p = 0.26) in the MEEI
sample (Table 2). Since the p53-PRO/PRO genotype showed
more evidence of association with NTG in the MEEI sample and
previous studies have suggested that NTG patients are more likely
to develop paracentral visual field defects at an early stage of the
disease [4,6], we examined the association between p53-PRO and
early paracentral visual field defects in the overall POAG sample
(both the NTG and HT-POAG patients).
We analyzed the earliest available visual fields that demonstrat-
ed a reliable significant defect (Figure 1) in the US cohort to assess
the association between the p53 codon72 polymorphism and
POAG stratified by pattern of visual field loss. 214 MEEI POAG
patients had qualifying visual fields and of these 67 had early-stage
paracentral defects. The p53-PRO/PRO genotype was more
frequent in the paracentral (PS) group (0.22) than in the nasal
step/arcuate (NS) group (0.04) or control group (0.05),
p = 2.761025 (Table 3). The odds of the C allele at p53-PRO
was over 2-fold higher in the PS group (p = 4.861024, age-
adjusted OR 2.20, 95%CI [1.43–3.39]) than in controls.
To replicate this finding in a second independent sample we
scored Humphrey visual fields for the GIST POAG cohort and
evaluated the distribution of p53 alleles in the PS and NS groups.
178 GIST patients had qualifying visual fields and of these 26 had
early-stage paracentral defects. In this sample the p53-PRO/PRO
genotype was also more frequent in the PS group (0.23) compared
with the NS group (0.05) and controls (0.07), (p = 7.361023), and
the p53-PRO C allele was also more common in the PS group
(p = 1.861023, age-adjusted OR 2.32, 95% CI [1.24–4.34])
(Table 3). After testing for heterogeneity we pooled the samples
Figure 1. Visual field scoring. The average pattern standard deviation (PSD) in each of 6 regions of the visual field corresponding to the superior
paracentral, inferior paracentral, superior nasal arcuate, inferior nasal arcuate, superior nasal step, and inferior nasal step were calculated for each
individual. Patients were classified as having paracentral scotomas (PS) if they had a mean PSD in one of the paracentral regions greater than 5 dB
and also if the mean PSD was more than 5 dB greater than any other visual field region. Patients were classified as having nasal step/arcuate
scotomas (NS) if one of the four possible nasal step or arcuate regions had a mean PSD greater than 5 dB and if one of the four possible regions was
5 dB greater than either of the paracentral regions. The visual field in panel A is an example of a PS, and panel B an example of an NS visual field. The
PSD plot in panel C corresponds to the visual field in panel B.
doi:10.1371/journal.pone.0045613.g001
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and performed a meta-analysis. We found an overall association of
the p53-PRO/PRO genotype with PS in the pooled sample
(p = 6.661027) and with the PRO allele in the meta-analysis
(1.361026, OR 2.17, 95% CI [1.58–2.98]). Stratification by
gender prior to analysis showed statistically significant association
between p53-PRO/PRO and paracentral scotoma formation in
both males and females with a somewhat stronger association in
males (p = 1.161024 in males vs p = 1.861023 in females; Table 4).
For the p53-PRO/PRO genotype the sensitivity and specificity to
detect early-stage paracentral scotoma formation in open angle
glaucoma patients is 0.22 and 0.95 respectively with a positive
predictive value of 0.6, and a negative predictive value of 0.80.
Table 2. Association of p53 codon 72 variant with NTG in the US (MEEI) cohort.
Group N Genotype Frequency (%) Allele Frequency (%)
CC CG GG p* C G p* OR (95%CI){
Age-adjusted OR
(95%CI){
All glaucoma 264 26
(9.9)
120
(45.4)
118
(44.7)
0.032 172
(32.6)
356
(67.4)
0.057 1.27
(1.00–1.61)
1.33
(1.03–1.73)
HT-POAG 200 16
(8.0)
91
(45.5)
93
(46.5)
0.26 123
(30.8)
277
(69.3)
0.28 1.16
(0.89–1.51)
1.20
(0.90–1.59)
NTG 64 10
(15.6)
29
(45.3)
25
(39.1)
0.003 49
(38.3)
79
(61.7)
0.016 1.63
(1.10–2.40)
1.88
(1.18–2.98)
Controls 400 19
(4.8)
183
(45.8)
198
(49.5)
221
(27.6)
579
(72.4)
*p values are calculated using Fisher’s exact test when compared to controls.
{OR and 95% CI are calculated using logistic regression when compared to controls.
Abbreviations: US, United States; MEEI, Massachusetts Eye and Ear Infirmary; POAG, Primary Open Angle Glaucoma; HT-POAG, High-tension glaucoma; NTG, Normal
Tension Glaucoma.
doi:10.1371/journal.pone.0045613.t002
Table 3. Association of p53 codon 72 variants with paracentral scotomas (PS) in the US and GIST cohorts.
Genotype Frequency (%) Allele Frequency (%)
N CC CG GG p* C G p* OR (95%CI){
Age-adjusted OR
(95%CI){ p-meta{
Common OR
(95%CI)
US All glaucoma 264 26
(9.9)
120
(45.4)
118
(44.7)
0.034 172
(32.6)
356
(67.4)
0.057 1.27
(1.00–1.61)
1.33
(1.03–1.73)
PS 67 15
(22.4)
28
(41.8)
24
(35.8)
2.761025 58
(43.3)
76
(56.7)
4.861024 2.00
(1.37–2.91)
2.20
(1.43–3.39)
NS 147 6
(4.1)
68
(46.3)
73
(49.6)
0.99 80
(27.2)
214
(72.8)
0.94 0.98
(0.73–1.32)
0.98
(0.70–1.36)
Controls 400 19
(4.8)
183
(45.8)
198
(49.5)
221
(27.6)
579
(72.4)
GIST All glaucoma 308 26
(8.4)
118
(38.3)
164
(53.3)
0.25 170
(27.6)
446
(72.4)
0.11 1.29
(0.95–1.75)
1.24
(0.91–1.67)
PS 26 6
(23.1)
11
(42.3)
9
(34.6)
7.361023 23
(44.2)
29
(55.8)
1.861023 2.69
(1.48–4.91)
2.32
(1.24–4.34)
NS 152 8
(5.3)
60
(39.5)
84
(55.2)
0.36 76
(25.0)
228
(75.0)
0.52 1.13
(0.79–1.62)
1.09
(0.75–1.57)
Controls 178 12
(6.7)
57
(32.0)
109
(61.2)
81
(22.8)
275
(77.2)
Pooled{ All glaucoma 572 52
(9.1)
238
(41.6)
282
(49.3)
0.041 342
(29.9)
802
(70.1)
0.046 1.21
(1.01–1.45)
1.21
(1.00–1.46)
0.011 1.28
(1.06–1.54)
PS 93 21
(22.6)
39
(41.9)
33
(35.5)
6.661027 81
(43.6)
105
(56.4)
2.961026 2.18
(1.59–3.00)
2.23
(1.57–3.16)
1.361026 2.17
(1.58–2.98)
NS 299 14
(4.7)
128
(42.8)
157
(52.5)
0.90 156
(26.1)
442
(73.9)
0.99 1.00
(0.80–1.25)
0.97
(0.76–1.24)
0.74 1.04
(0.83–1.31)
Controls 578 31
(5.4)
240
(41.5)
307
(53.1)
302
(26.1)
854
(73.9)
*p values are calculated using Fisher’s exact test when compared to controls.
{OR and 95% CI are calculated using logistic regression when compared to controls.
{p-heterogeneity .0.05 (Breslow-Day test between cohorts). Meta-analysis assumed a fixed-effect, and common OR and 95%CI are calculated using the Mantel-
Haenszel method.
Abbreviations: US, United States; GIST, Glaucoma Inheritance Study in Tasmania; PS, Paracentral Scotoma; NS, Nasal Step/Arcuate Scotoma.
doi:10.1371/journal.pone.0045613.t003
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Discussion
The results of this study suggest that the p53 codon 72 PRO/
PRO genotype is potentially associated with early-stage paracen-
tral visual field defects in patients with open-angle glaucoma. This
is the first study to assess association of p53 with glaucoma subsets
defined by visual field stratification. Our subgroup analysis could
suggest that the previously observed inconsistent association
between p53 codon 72 and glaucoma may reflect differences in
the composition of the study cohorts with respect to early-onset
paracentral cases due to differences in ascertainment methodol-
ogies and case definitions. The significant association between the
p53 variant and paracentral visual loss among POAG cases vs
controls that we discovered in our US cohort was confirmed in the
Australian cohort. These results could point to another allele in
linkage disequilibrium with the p53 codon 72 variant that is
biologically significant; however, considering the known biological
activity of the codon 72 polymorphism this possibility seems less
likely.
The p53 codon 72 polymorphism influences apoptosis, and the
apoptotic potential of the different forms of the protein is
dependent on the cell type and cellular environment. p53 activity
is determined by the mix of p53 activators and stimulators present
in a particular cell type [33]. Stimulators and inhibitors bind
specifically to the PXXP motif that contains the codon 72
polymorphic site, and p53-PRO binds both inhibitors and
stimulators more efficiently than p53-ARG [30]. Depending on
the relative amounts of inhibitors and stimulators the p53-PRO
form may have more or less apoptotic activity than p53-ARG. In
vitro studies using a variety of tumor cells have suggested that p53-
ARG has more apoptotic activity than p53-PRO, including a
more effective response to oxidative stress and more efficient
translocation to the mitochondria [34]. However this relative
increase in p53-ARG activity is due to increased activity of the p53
inhibitor iASPP (inhibitory member of the apoptosis-stimulating
protein of p53), which reduces the activity of the p53-PRO form
but not the p53-ARG form [33]. Interestingly, under conditions of
low oxygen tension, the p53-PRO form induces more cell death in
cancer cells than p53-ARG [15] and under these conditions the
p53 stimulators may be more abundant rendering the p53-PRO
form more active. Our results suggest that the p53-PRO has more
apoptotic activity in glaucoma, which may reflect variable
expression of p53 stimulators and inhibitors in cell types involved
in the disease. The p53-PRO apoptotic potential could be
enhanced by conditions creating low retinal oxygen tension such
as sleep apnea, a condition previously demonstrated to be
associated with initial paracentral scotoma formation in glaucoma
[4].
Our results could suggest that the ganglion cells in the
maculopapillary bundle are more susceptible to p53-mediated
apoptosis. The maculopapillary bundle is recognized to be more
susceptible to certain metabolic conditions (such as methyl alcohol
toxicity) and genetic defects (such OPA1 mutations in dominant
Table 4. Association of p53 codon 72 variants with paracentral scotomas (PS) in the US and GIST cohorts stratified by gender.
Genotype Frequency (%) Allele Frequency (%)
N CC CG GG p* C G p*
OR
(95%CI){
Age-adjusted
OR (95%CI){ p-meta{
Common OR
(95%CI)
US Male PS 27 7
(25.9)
13
(48.2)
7
(25.9)
0.0010 27
(50.0)
27
(50.0)
0.0012 2.73
(1.52–4.89)
3.15
(1.61–6.18)
Controls 179 9
(5.0)
78
(43.6)
92
(51.4)
96
(26.8)
262
(73.2)
Female PS 40 8
(20.0)
15
(37.5)
17
(42.5)
0.0051 31
(38.8)
49
(61.2)
0.064 1.60
(0.98–2.63)
1.68
(0.95–3.00)
Controls 221 10
(4.5)
105
(47.5)
106
(48.0)
125
(28.3)
317
(71.7)
GIST Male PS 6 3
(50.0)
1
(16.7)
2
(33.3)
0.035 7
(58.3)
5
(41.7)
0.036 4.31
(1.26–14.74)
2.27
(0.62–8.36)
Controls 53 5
(9.4)
16
(30.2)
32
(60.4)
26
(24.5)
80
(75.5)
Female PS 20 3
(15.0)
10
(50.0)
7
(35.0)
0.041 16
(40.0)
24
(60.0)
0.018 2.36
(1.17–4.76)
2.45
(1.18–5.11)
Controls 125 7
(5.6)
41
(32.8)
77
(61.6)
55
(22.0)
195
(78.0)
Pooled{ Male PS 33 10
(30.3)
14
(42.4)
9
(27.3)
1.161024 34
(51.5)
32
(48.5)
7.161025 2.98
(1.76–5.04)
2.90
(1.62–5.21)
2.861025 2.96
(1.75–5.01)
Controls 232 14
(6.0)
94
(40.5)
124
(53.5)
122
(26.3)
342
(73.7)
Female PS 60 11
(18.3)
25
(41.7)
24
(40.0)
0.0018 47
(39.2)
73
(60.8)
0.0041 1.83
(1.22–2.74)
1.89
(1.21–2.95)
0.0034 1.82
(1.21–2.72)
Controls 346 17
(4.9)
146
(42.2)
183
(52.9)
180
(26.0)
512
(74.0)
*p values are calculated using Fisher’s exact test when compared to controls.
{OR and 95%CI are calculated using logistic regression when compared to controls.
{p-heterogeneity .0.05 (Breslow-Day test between cohorts). Meta-analysis assumed a fixed-effect, and common OR and 95% CI are calculated using the Mantel-
Haenszel method.
Abbreviations: US, United States; GIST, Glaucoma Inheritance Study in Tasmania; PS, Paracentral Scotoma.
doi:10.1371/journal.pone.0045613.t004
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optic atrophy) that impair mitochondrial function [35]. The
mitochondrial density is higher in the maculopapillary bundle [36]
and these cells have higher levels of reactive oxygen species that
may lower the apoptotic threshold. The maculopapillary bundle
may be more vulnerable to the effects of UV light [37] which
could influence mitochondrial function and lower the threshold for
apoptosis in carriers of p53-PRO. Early-stage paracentral defects
are more common in NTG patients [4] and NTG patients are
more likely to have abnormalities of ocular blood flow [38]
suggesting that ocular perfusion may also contribute to the
increased susceptibility of p53 mediated apoptosis in the paracen-
tral region.
The population frequencies of the PRO/PRO genotype support
a role for the p53-PRO allele in glaucoma. p53-ARG is unique to
humans, and while the arginine allele is the most common allele in
Caucasian populations, the ancestral proline allele is the most
common allele in African populations, an ethnic group known to
have increased risk of glaucoma [39]. The PRO/PRO genotype is
found in 47% of sub-Saharan Africans compared with 8% of
European whites. The PRO/PRO genotype is also more common
in Japanese (28%) than in European whites, a population with an
increased prevalence of normal tension glaucoma [40].
Our results demonstrate a potential association between p53-
PRO allele and early-stage paracentral scotoma formation in
glaucoma. Several limitations of our study should be considered.
First, the number of paracentral cases is low for a formal
association study and it is possible that these results could be
subject to type II statistical error. Furthermore, while we replicated
our findings here, confirmation of these observations in additional
datasets will be necessary before a formal association between p53
codon 72 alleles and paracentral scotoma can be established.
Second, the low allele frequency and corresponding low sensitivity
indicates that testing for the p53-PRO/PRO genotype would not
be useful as an overall glaucoma population screening test. The
specificity of the association could help identify a subset of
glaucoma patients who are at increased risk for early loss of central
vision once a formal association is established. Third, these
findings are limited to Caucasian patients with European ancestry
and may not be generalizable to other populations. Finally, we
found that the potential association between p53-PRO/PRO and
paracentral scotoma is somewhat stronger in males than in females
possibly suggesting that the contribution of p53-PRO is influenced
by gender, however further study in other datasets would be
required to confirm this observation.
Retinal ganglion cells that degenerate to cause central vision loss
may be differentially susceptible to apoptosis and our results
suggest that p53 is one protein that could influence this
susceptibility. The regulation of glaucomatous ganglion cell
apoptosis is clearly complex and it is likely that multiple genetic
and environmental factors will contribute to this process. Recent
studies have identified a number of genes, in addition to p53, with
altered expression in glaucomatous ganglion cells [41,42].
Examining these genes and their respective pathways will help
dissect the underlying genetic causes of early-stage paracentral
scotoma formation in glaucoma. Identifying factors that influence
the development of paracentral scotomas will be an important step
toward preventing visual loss in patients with glaucoma.
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